Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PW Medtech GroupFRA:PWE -0.98%57 Return-on-Tangible-Asset is 1.55% as of Dec. 2025, which is 69% below its 10-year median of 4.98. GuruFocus rates FRA:PWE with a GF Score™ of 57/100 and a GF Value™ of €0.13 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 854 Medical Devices & Instruments companies, PW Medtech Group ranks better than 57.49% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. PW Medtech Group's annualizedNet Income for the quarter that ended in Dec. 2025 was €6.88 Mil. PW Medtech Group's average total tangible assets for the quarter that ended in Dec. 2025 was €444.08 Mil. Therefore, PW Medtech Group's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 1.55%.
The historical rank and industry rank for PW Medtech Group's Return-on-Tangible-Asset or its related term are showing as below:
FRA:PWE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.6 Med: 4.98 Max: 41.45
Current: 2.62
During the past 13 years, PW Medtech Group's highest Return-on-Tangible-Asset was 41.45%. The lowest was 1.60%. And the median was 4.98%.
FRA:PWE's Return-on-Tangible-Asset is ranked better than 57.49% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.735
vs FRA:PWE: 2.62
PW Medtech Group (FRA:PWE) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
PW Medtech Group Return-on-Tangible-Asset Related Terms
PW Medtech Group Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for PW Medtech Group's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:PWE vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, PW Medtech Group's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PW Medtech Group Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PW Medtech Group's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where PW Medtech Group's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 1.55% mean?
PW Medtech Group (FRA:PWE) has a Return-on-Tangible-Asset of 1.55% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PW Medtech Group and its competitors. This is 69% below median its historical median of 4.98. Over the past decade, PW Medtech Group's Return-on-Tangible-Asset has ranged from 1.60 to 41.45. According to the industry distribution chart, PW Medtech Group ranks #363 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 42.5%.
Is PW Medtech Group's Return-on-Tangible-Asset too high?
PW Medtech Group's current Return-on-Tangible-Asset of 1.55% is 69% below median its 10-year median of 4.98. Over the past 10 years, this metric has ranged from a low of 1.60 to a high of 41.45. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.74. PW Medtech Group's value of 1.55% is 110.9% above this industry median. Based on the distribution chart, PW Medtech Group ranks #363 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, PW Medtech Group has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PW Medtech Group's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, PW Medtech Group ranks #363 out of 854 companies for Return-on-Tangible-Asset. This puts PW Medtech Group in the upper half of its industry. The industry median Return-on-Tangible-Asset is 0.74. PW Medtech Group's value of 1.55% is 110.9% above this benchmark. Historically, PW Medtech Group's own Return-on-Tangible-Asset has ranged from 1.60 to 41.45 over the past decade. While the company's 10-year median is 4.98 vs. the industry median of 0.74, PW Medtech Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.74, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PW Medtech Group's current Return-on-Tangible-Asset of 1.55% is 110.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on PW Medtech Group and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PW Medtech Group's current Return-on-Tangible-Asset is 1.55%, which is 69% below median its own 10-year median of 4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PW Medtech Group stock overvalued right now?
Based on GuruFocus' analysis, PW Medtech Group (FRA:PWE) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.13, compared to a current price of €0.10 — trading 22.3% below its estimated fair value. The current Return-on-Tangible-Asset is 1.55%, which is 69% below median its 10-year median of 4.98 and 110.9% above the Medical Devices & Instruments industry median of 0.74. PW Medtech Group's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For PW Medtech Group (FRA:PWE), the current Return-on-Tangible-Asset is 1.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PW Medtech Group (FRA:PWE) Overvalued in 2026?
Based on GuruFocus' analysis, PW Medtech Group stock appears to be undervalued.
The current stock price of €0.10 is trading 22.3% below its estimated GF Value™ of €0.13.
GuruFocus considers PW Medtech Group to be Modestly Undervalued.
Key valuation signals for FRA:PWE:
Return-on-Tangible-Asset: 1.55% (69% below median its 10-year median of 4.98)
GF Value™: €0.13 vs. price of €0.10 (22.3% below fair value)
Industry Position: 110.9% above the Medical Devices & Instruments median (#363 of 854)
No single metric tells the full story. See the FRA:PWE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PW Medtech Group Ltd is a medical device company focused on China's medical device industry. The Group operates in infusion sets, blood purification products, and regenerative medical biomaterials. Its products include non-PVC-based infusion sets, precision filter infusion sets, light-resistant infusion sets, intravenous cannula products, insulin needles and pens, high flux and low flux hemodialyzers, hemodiafilters, hemoperfutors, and dialysis machines. Its segments are Infusion Set Business, Blood Purification Business, which represents the R&D, manufacturing, and sales of hemodialysis and blood purification medical devices, and Regenerative Medical Biomaterials Business, which generates maximum revenue. Geographically, it operates in China, North America, India and Others.
57GF Score
Get the complete analysis for FRA:PWE
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PWE has been successfully added to your 
